Predictive Oncology Dirección

Dirección controles de criterios 3/4

El CEO de Predictive Oncology's es Raymond Vennare , nombrado en Nov 2022, tiene una permanencia de 1.42 años. compensación anual total es $525.00K, compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.18% de las acciones de la empresa, por valor de $9.19K. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 3.2 años, respectivamente.

Información clave

Raymond Vennare

Chief Executive Officer (CEO)

US$525.0k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	1.4yrs
Participación del CEO	0.2%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Jun 29

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Raymond Vennare en comparación con los beneficios de Predictive Oncology?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$525k	US$525k	-US$14m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$639k	US$88k	-US$26m
Sep 30 2022	n/a	n/a	-US$26m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$33k	n/a	-US$20m

Compensación vs. Mercado: La compensación total ($USD525.00K) de Raymond está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD667.11K).

Compensación vs. Ingresos: La compensación de Raymond ha sido consistente con los resultados de la empresa en el último año.

CEO

Raymond Vennare (70 yo)

1.4yrs

Permanencia

US$525,000

Compensación

Mr. Raymond F. Vennare is Chief Executive Officer and Chairman at Predictive Oncology Inc. from November 01, 2022. He Co-Founded ThermalTherapeutic Systems, Inc. in 2006 and served as its Executive Vice Pr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Raymond Vennare	CEO & Chairman	1.4yrs	US$525.00k	0.18% $ 9.2k
Joshua Blacher	Interim Chief Financial Officer	less than a year	sin datos	sin datos
Theresa Ferguson	Senior Director of Marketing	2yrs	sin datos	sin datos
Lawrence DeLucas	Senior Vice President of Biologics	no data	sin datos	sin datos
Arlette Uihlein	Senior VP of Translational Medicine & Drug Discovery and Medical Director	no data	sin datos	sin datos

1.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de POAI no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Raymond Vennare	CEO & Chairman	2.6yrs	US$525.00k	0.18% $ 9.2k
Bernard Harris	Member of Business Advisory Board	less than a year	sin datos	sin datos
Charles Nuzum	Lead Independent Director	3.8yrs	US$98.90k	sin datos
Andrew Einhorn	Member of Business Advisory Board	less than a year	sin datos	sin datos
Veena Rao-Mirmira	Independent Director	less than a year	US$73.34k	0.22% $ 11.8k
Marc Malandro	Member of Scientific Advisory Board	5.6yrs	sin datos	sin datos
Daniel Handley	Independent Director	4.2yrs	US$54.45k	0.46% $ 24.1k
Robert Murphy	Member of Scientific Advisory Board	5.6yrs	sin datos	sin datos
Matthew Hawryluk	Independent Director	1.4yrs	US$65.56k	0.23% $ 12.2k
Nancy Chung-Welch	Independent Director	3.8yrs	US$118.34k	0.52% $ 27.4k
Gregory St. Clair	Independent Director	3.8yrs	US$65.56k	0.55% $ 29.1k
Christoph Reinhard	Member of Scientific Advisory Board	less than a year	sin datos	sin datos

3.2yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de POAI se considera experimentada (3.2 años de antigüedad promedio).

Predictive Oncology Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Predictive Oncology Inc. Announces Executive Changes

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

High number of new and inexperienced directors

Recent updates

New minor risk - Share price stability

New major risk - Market cap size

Full year 2023 earnings released: US$3.48 loss per share (vs US$7.05 loss in FY 2022)

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Third quarter 2023 earnings released: US$0.79 loss per share (vs US$1.04 loss in 3Q 2022)

Predictive Oncology Inc. to Report Q3, 2023 Results on Nov 14, 2023

Predictive Oncology Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$3.02 loss in 2Q 2022)

Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Predictive Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

First quarter 2023 earnings released: US$0.86 loss per share (vs US$1.02 loss in 1Q 2022)

Predictive Oncology Inc. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in FY 2021)

Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer

Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Board

Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company's Scientific Advisory Board

Predictive Oncology Appoints Matthew J. Hawryluk Ph.D. to the Board of Directors

Price target increased to US$5.00

Third quarter 2022 earnings released: US$0.052 loss per share (vs US$0.083 loss in 3Q 2021)

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Appoints David S. Smith to the Company's Board of Directors

Predictive Oncology Appoints Raymond F. Vennare as Chief Executive Officer Effective November 1, 2022

Predictive Oncology has a new CEO

Predictive Oncology Inc., Annual General Meeting, Dec 01, 2022

Predictive Oncology Inc. Announces Retirement of J. Melville (“Mel”) Engle as Chairman and A Member of Board of Directors

Predictive Oncology announces retirement of CEO Mel Engle

Second quarter 2022 earnings released: US$0.075 loss per share (vs US$0.05 loss in 2Q 2021)

Predictive Oncology Inc. Announces Unaudited Consolidated Impairment Charges for the Three Months Ended June 30, 2022

Predictive Oncology Appoints Julia Kirshner as Chief Scientific Officer, Effective August 1, 2022

Predictive Oncology Inc. Announces Christina Jenkins Intends to Resign as Director, Effective August 31, 2022

Insider recently bought US$62k worth of stock

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$4.50

Predictive Oncology Inc. Appoints Theresa Ferguson as Senior Director of Marketing

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Inc. Reports Strong Results from Its AA Cancer Drug Evaluation

High number of new directors

Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million.

Third quarter 2021 earnings released: US$0.083 loss per share (vs US$0.46 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.36 loss in 2Q 2020)

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.93 loss in 1Q 2020)

Director has left the company

CEO & Director Carl Schwartz has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$6.86 loss in FY 2019)

Predictive Oncology’S, Skyline Medical Division, Developing Generation 3 Direct-To-Drain Automated Fluid Waste Management System

Predictive Oncology Inc. Completes Key Data Generation Milestones in Its Retrospective Study

Predictive Oncology Inc. announced that it expects to receive $17.635344 million in funding

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $7.389004 million.

Predictive Oncology Announces the Start of Its Drug Repurposing Project Using Its Ground-Breaking Pedal™ Platform for Ovarian Cancer

New 90-day high: US$1.40

Predictive Oncology Regains Compliance with Nasdaq Minimum Bid Price Requirement

Predictive Oncology regains Nasdaq compliance

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $4.097964 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $2.2 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $3.074007 million.

New 90-day high: US$0.90

Third quarter 2020 earnings released: US$0.46 loss per share

New 90-day low: US$0.72

Predictive Oncology Receives A Letter from the Listing Qualifications Department Nasdaq Stock Market

Predictive Oncology Inc. announced that it has received $1.370002 million in funding

Precision Therapeutics Inc. Announces Executive Appointments